Annexon, Inc.
NASDAQ:ANNXBiotechnology
-$0.04 today
- Market cap
- $576.73M
- Beta
- 1.18
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.01
Volume 2.98M
Average 2.56M
ANNX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Annexon, Inc.NASDAQ: ANNX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $10.27M rose 11.3% year over year, ahead of the -0.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 25.0% from the prior quarter. Over 3 fiscal years it compounded at +0.8% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -8.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $10.27M+25.0% QoQ
- Last fiscal yearDec 2025
- $31.71M-8.4% YoY
- LTMMar 2026
- $32.75M-0.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.3% | -100.0% | -111.3 pp |
| 1 year | -8.4% | -100.0% | -91.6 pp |
| 3-year CAGR | +0.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 31.71M USD
- Year-over-year change
- -8.4%
- 4-year CAGR
- +0.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.71M | -8.4% |
| FY2024 | 2024-12-31 | 34.63M | +23.6% |
| FY2023 | 2023-12-31 | 28.02M | -9.5% |
| FY2022 | 2022-12-31 | 30.95M | +1.0% |
| FY2021 | 2021-12-31 | 30.65M | — |
Selling, General & Admin vs competitors
How ANNX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -0.8% is the 7th highest of 11, against a peer median of +4.7%.
- Over three fiscal years its annual growth of +0.8% compares with a peer median of +10.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $77.08M USD | +17.2% | +94.2% | 1041.9% |
| FY2025 | €72.87M EUR | +87.3% | +113.4% | — | |
| LTM Sep 2026 | $69.54M USD | -16.7% | +16.7% | 980.1% | |
| LTM Jun 2026 | $65.29M USD | +5.1% | +10.3% | 62.2% | |
| LTM Mar 2026 | $62.81M USD | +42.2% | +11.5% | 27.0% | |
| LTM Mar 2026 | $54.46M USD | -19.1% | +6.0% | 94.0% | |
| LTM Mar 2026 | $32.75M USD | -0.8% | +0.8% | — | |
| LTM Mar 2026 | $22.58M USD | +5.5% | -4.4% | 269.8% | |
| LTM Mar 2026 | $17.08M USD | -4.8% | +20.7% | 31.8% | |
| LTM Mar 2026 | €14.24M EUR | -27.6% | +7.0% | 48538.7% | |
| LTM Mar 2026 | CHF 11.38M CHF | +4.4% | +6.7% | 307.5% | |
| Peer median (excluding ANNX) | — | +4.7% | +10.9% | 269.8% | |
Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 3.45M | 3.69M |
| Gross Profit | 0 | 0 | 0 | (3.45M) | (3.69M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 100.07M | 112.5M | 113.76M | 119.45M | 184.7M |
| Selling, General & Admin | 30.65M | 30.95M | 28.02M | 34.63M | 31.71M |
| Operating Expenses | 130.71M | 145.6M | 143.72M | 150.62M | 212.72M |
| Depreciation & Amortization | 2.14M | 2.15M | 2.15M | 3.45M | 2.65M |
| EBITDA | (128.18M) | (139.8M) | (132.09M) | (134.75M) | (204.04M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (130.71M) | (145.6M) | (143.72M) | (154.07M) | (216.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 390K | 3.65M | 9.49M | 15.87M | 9.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 390K | 3.65M | 9.49M | 15.87M | 9.72M |
| Income Before Tax | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.34) | (2.60) | (1.77) | (1.01) | (1.34) |
| EPS (Diluted) | (3.34) | (2.60) | (1.77) | (1.01) | (1.34) |
| Weighted Avg Shares | 38.32M | 54.67M | 75.67M | 137.4M | 155.11M |
| Weighted Avg Shares (Diluted) | 38.32M | 54.67M | 75.67M | 137.4M | 155.11M |
Annexon, Inc.
NASDAQ:ANNX
Intrinsic Alpha fair value
Locked
Current Price
$3.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.